Table 3 Top 20 ranked miRNA-mRNA interaction pairs (GBM).
From: Integrated analysis of microRNA-target interactions with clinical outcomes for cancers
miRNA | Gene | p-value (HL:LH) | Gene Description |
|---|---|---|---|
hsa-miR-19b-3p | GPATCH8 | 8.37E-06 | G Patch Domain Containing 8 |
hsa-miR-19b-3p | CLIP1 | 2.01E-05 | CAP-GLY domain containing linker protein 1 |
hsa-miR-19b-3p | CTR9 | 2.21E-05 | Ctr9, Paf1/RNA polymerase II complex component, homolog (S. cerevisiae) |
hsa-miR-34a-5p | HIST3H2A | 3.11E-05 | Histone cluster 3, H2a |
hsa-miR-106a-5p | CDKN1A* | 4.43E-05 | Cyclin-dependent kinase inhibitor 1A (p21, Cip1) |
hsa-miR-145-5p | FAM3C* | 6.87E-05 | Family with sequence similarity 3, member C |
hsa-miR-19b-3p | PRKAA1 | 8.53E-05 | Protein kinase, AMP-activated, alpha 1 catalytic subunit |
hsa-miR-34a-5p | MTAP* | 8.94E-05 | Methylthioadenosine phosphorylase |
hsa-miR-20a-5p | CDKN1A* | 9.77E-05 | Cyclin-dependent kinase inhibitor 1A (p21, Cip1) |
hsa-miR-148a-3p | HOXC8 | 1.20E-04 | Homeobox C8 |
hsa-miR-221-3p | TFAP2A | 1.28E-04 | Transcription factor AP-2 alpha (activating enhancer binding protein 2 alpha) |
hsa-miR-19a-3p | HOXA5 | 1.29E-04 | Homeobox A5 |
hsa-miR-200b-3p | RIN2 | 1.37E-04 | Ras and Rab interactor 2 |
hsa-miR-26b-5p | CLEC5A | 1.43E-04 | C-type lectin domain family 5, member A |
hsa-miR-19b-3p | PSMD9 | 1.77E-04 | Proteasome (prosome, macropain) 26S subunit, non-ATPase, 9 |
hsa-miR-19b-3p | LPHN2 | 1.91E-04 | Latrophilin 2 |
hsa-miR-34a-5p | ATXN2L | 2.08E-04 | Ataxin 2-like |
hsa-miR-17-5p | CDKN1A* | 2.44E-04 | Cyclin-dependent kinase inhibitor 1A (p21, Cip1) |
hsa-miR-222-3p | KIT* | 2.50E-04 | V-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog |
hsa-miR-19b-3p | ATM* | 2.54E-04 | Ataxia telangiectasia mutated |